Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00271
|
|||||
| Drug Name |
Empagliflozin
|
|||||
| Synonyms |
(1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; 864070-44-0; AK160980; BI 10773; BI-10773; BI10773; CHEBI:82720; Empagliflozin (BI 10773); HDC1R2M35U; JARDIANCE; UNII-HDC1R2M35U
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Type 1 diabetes [ICD11:5A10] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C23H27ClO7
|
|||||
| Canonical SMILES |
C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl
|
|||||
| InChI |
InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1
|
|||||
| InChIKey |
OBWASQILIWPZMG-QZMOQZSNSA-N
|
|||||
| CAS Number |
CAS 864070-44-0
|
|||||
| Pharmaceutical Properties | Molecular Weight | 450.9 | Topological Polar Surface Area | 109 | ||
| Heavy Atom Count | 31 | Rotatable Bond Count | 6 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 7 | |||
| XLogP |
2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
135267035
,136350032
,137759455
,160647541
,160671533
,162201844
,163620871
,170500874
,172232552
,17390987
,178101464
,186021010
,189024748
,198945623
,206246269
,211535427
,223447440
,223471392
,223602217
,223701070
,227166637
,23917761
,241383513
,242077478
,245606277
,249737155
,249865857
,251963060
,252067199
,252159682
,252215347
,35020536
,80625411
|
|||||
| ChEBI ID |
ChEBI:82720
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Empagliflozin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01913) | |||||
| 3 | KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (dg:DG01665) | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.